Bioprocessing & Manufacturing

 

 

With new vaccine formulations and technology platforms, vaccine developers need to have the right processes in place to manufacture them during clinical trials and at commercial scale. Use this opportunity to meet with the manufacture and bioprocessing leads who need services for all of the latest manufacturing challenges, from formulating and manufacturing adjuvants, mRNA platforms, VLPs and viral vectors, to technology transfer and continuous manufacturing.

 

DOWNLOAD DRAFT AGENDA

 

2018 AGENDA

 

Bioprocess & Manufacture, Wednesday 4 April 2018

Vaccine Bioprocessing

Parrish Galliher
Bioprocess & Manufacture
09:40

Practical solutions enabling rapid production of viral based therapies

Dr Ahd Hamidi
Bioprocess & Manufacture
10:10

Latest advancements in production process intensification to support demand for affordable vaccines

  • Use of fixed-bed bioreactors
  • Development of microfacilities
Dr Pascal Longchamp
Bioprocess & Manufacture
10:25

Long range production platform for pharmaceuticals: Application to CRM197

10:40

Networking coffee break

Dr Don Gerson
Bioprocess & Manufacture
11:40

What can we learn from mAB bioprocessing to vaccines to make more vaccines? From R&D to full scale manufacturing and worldwide distribution

  • The transition from lab to manufacturing and large-scale production of low cost vaccines globally
Dr Wilfried Bakker
Bioprocess & Manufacture
12:10

Bridging the Global Health Gap – Viral and bacterial vaccine development at Intravacc

Vaccine Production and Delivery Systems

Dr Max Søgaard
Bioprocess & Manufacture
12:25

ExpreS2 – an insect cell based vaccine production system suitable for difficult-to-express proteins

Elizabeth Joseph
Bioprocess & Manufacture
12:40

Analytical characterization of aluminum adsorbed vaccines: Stability indicating methods for product release

  • What general guidance is there on release and stability test methods for aluminum adsorbed vaccines?  
  • Understanding of the antigen stability following adsorption
  • Reviewing potential release tests and proposing a panel of stability indicating tests for aluminum adsorbed vaccines
1:10

Networking Lunch & Poster Session

Darin Zehrung
Bioprocess & Manufacture
2:40

Review of the current alternative vaccine delivery methods and how their effectiveness is assessed

  • The advantages and progression of up taking alternative delivery systems and packaging
  • The logistical challenges to consider for developing countries
  • How to make new technologies applicable and build a stronger business case to be used
  • Total system effectiveness: Cost modelling of delivery systems
Michael A. Schrader
Bioprocess & Manufacture
3:10

Creating the next generation of vaccines and immunotherapies by mimicking an infection to enhance the immune response

  • Illustrating how the delivery of sustained release vaccine depots via microneedle patch improves immunogenicity
  • Logistical conquest in easy administration, shelf life stability and only minutes of wear time
  • Current progress with an in-house influenza vaccine and partnered programs to advance formulation for optimal patient uptake
Dr Ahmad Ghoniem
Bioprocess & Manufacture
3:25

A patch and a laser = vaccination without a cold chain?

Dr Victor Ayala
Bioprocess & Manufacture
3:40

Accelerating vaccine production using a non-viral enabling technology for cell engineering

  • Discuss Phase I, fully-scalable technology that allows efficient, cost-effective evaluation of vaccine candidates
  • Learn about the role media has on antigen folding, expression and glycosylation for transfection
  • Review customized purification techniques and characterization assays to overcome variability
4:10

Networking coffee break

Bioprocess needs for the developed & developing world

Peter Khoury
Bioprocess & Manufacture
4:40

Vaccine self-sufficiency and responding to pandemic outbreaks from small to large scale

  • Understanding in securing strains, safety,  regulatory hurdles and manufacturing hurdles
  • Considering the logistics of distribution
Ranjeet Patil
Bioprocess & Manufacture
5:10

A new paradigm for vaccine process development: solving challenges through supplier-manufacturer collaborations

Dr Yan-ping Yang
Bioprocess & Manufacture
5:40

Continuous Process for Vaccine Manufacturing: Challenges and opportunities

  • Experiences & lessons learned from the industry on continuous processing
  • Disposable technology & continuous technology: a powerful combination
  • Rapid technology advancement for key enablers to support continuous processing
  • FDA Fully on Board with the Concept of continuous processing
6:10

Chair’s closing remarks and close of congress day 2

6:15

Networking Drinks & Party

last published: 02/Apr/18 21:25

Bioprocess & Manufacture, Thursday 5 April 2018

Enabling Technologies from Discovery to Market

Prof Fikri Avci
Bioprocess & Manufacture
09:10

Understanding how vaccines elicit immune responses

Dr Seth Thomas
Bioprocess & Manufacture
09:40

Enabling translation of vaccine discovery into clinical candidates in academia

Dr Fiona Lin
Bioprocess & Manufacture
10:10

Designing vaccines focusing on critical quality attributes and analytical strategies

10:40

Networking coffee break

Dr Viliam Pavliak
Bioprocess & Manufacture
11:30

Developing vaccines for developing countries – A case study on Typhoid conjugate vaccine

12:30

Networking Lunch & Poster Session

AFTERNOON PLENARY OF CONGRESS

Dr Angela Shen
1:40

Report on U.S. vaccine development and innovation including the current landscape, existing challenges, and drivers and levers to incentivize development

  • A combined effort from HHS, NIH, CDC, FDA, BARDA to promote innovation in the development of vaccines that minimize the burden of infectious disease
  • What is the optimal process to determine which vaccines would be beneficial to public health and how information on such vaccines is disseminated to key stakeholders
  • Identifying whether obstacles exist that inhibit the development of beneficial vaccines
  • Recommendations on how best to promote and incentivize vaccine innovation and development
Dr Jeffrey Stoddard
2:10

Zoster vaccine recombinant, adjuvanted: A journey from research to approval

  • Non-live, recombinant vaccine to help prevent herpes zoster (shingles), combining glycoprotein E with an adjuvant system, AS01
  • Sharing positive results from Phase III revaccination study 
Dr Walter A Orenstein
2:40

With polio eradication succeeding, should measles eradication come next?

  • Changing the perception from polio: Focusing on measles elimination to build our overall immunization program
  • Using a “diagonal” approach when dealing with highly contagious preventable diseases like measles
  • Surveillance -  a weakness in our system?
  • Cost of controlling outbreaks and the consequences
Dr Paul Offit
3:10

Vaccine hesitancy: How to respond to the media to advance better health

  • Challenges to communicating science through the opaque prism of the media
  • How certain cultural biases can influence the perception of science 
3:40

3:40 Chair closing remarks and end of congress

last published: 02/Apr/18 21:25

 

Get Involved At World Vaccine Congress Washington

 

To Sponsor Or Exhibit

Marc Rhys-Evans
marc.rhys-evans@terrapinn.com
+44 20 7827 5945

 

 

 

To Register

Tayyab Abbasi
tayyab.abbasi@terrapinn.com
+44 20 7092 1210

 

 

 

Press Relations

Karina Kusova
karina.kusova@terrapinn.com
+44 20 7092 1071